I'm Passing on Pfizer Stock in 2024. Here's Why.

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic world. Over the last couple of years, demand for Pfizer's COVID-19 treatments helped spur record-breaking revenue.

However, as pandemic concerns wane, some investors may wonder where Pfizer's next growth engine lies. While the company has several catalysts identified, I have my doubts on their prospects. And I'm not the only one. With the stock trading at just $29 per share, Pfizer shares are currently hovering around their lowest levels in 10 years.

Let's dig into the current state of Pfizer and assess if now is an opportunity to buy the dip, or move on and seek growth elsewhere.

Source Fool.com

Pfizer Inc. Aktie

Pfizer Inc. muss heute Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -2,85 % tiefer.
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 27.61 € bedeuten.

Like: 0

PFE

Teilen